
    
      Multi-centre, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study
      of Lu AE58054 as add-on to donepezil. The patient has probable Alzheimer's Disease consistent
      with the National Institute of Neurological and Communicative Disorders and Stroke and the
      Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
    
  